Marjan J. Cruijsen

Eindhoven, NB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.

Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 31, 2025

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Journal: Blood neoplasia

Published: December 02, 2025

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Journal: Haematologica

Published: May 08, 2025

Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.

Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.

Journal: European journal of haematology

Published: August 25, 2024

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Journal: Annals of hematology

Published: July 23, 2024

Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps.

Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps.

Journal: Frontiers in immunology

Published: May 24, 2023

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.

Journal: Blood

Published: May 14, 2021

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.

Journal: Haematologica

Published: May 10, 2021

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.

Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: November 22, 2020

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.

Journal: Leukemia & lymphoma

Published: June 13, 2020

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Journal: Leukemia research

Published: March 22, 2018

DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4+CD25high FOXP3+ Regulatory T Cells but Does Not Affect Their Suppressive Capacity.

DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4+CD25high FOXP3+ Regulatory T Cells but Does Not Affect Their Suppressive Capacity.

Journal: Journal of immunology research

Published: October 30, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026